SB202190 (FHPI)

Catalog No.S1077

SB202190 (FHPI) Chemical Structure

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 17 Publications

3 Customer Reviews

  • C, Jurkat cells with SB202190 at 1, 5, and 10 μM were tested, and a decreased SRP72 expression was found when using at 10 μM (lanes 8 and 9). D, results were analyzed and RUA illustrated, finding significant results at 10 μM at 240 versus 0 and 120 versus 0 min (p<0.05).

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

    C, effect of SB202190 (1, 5, and 10 μM) on SRP72 phosphorylation was tested. A decreased intensity of SRP72 expression when used at 1 μM (240 min) and 5 and 10 μM (120 and 240 min) was found. D, RUA illustrated obtaining significant results at concentration 5 and 10 μM at 120 versus 0 and 240 versus 0 min. * indicates p<0.05.

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

  • We used real time RT-PCR to investigate the effects of SB202190 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824–32833. SB202190 (FHPI) purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Targets
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 NV3CU41xTnWwY4Tpc44hSXO|YYm= NF7GOXkzPSEQvF2= NULGSHVTOzBibXnu NUfEV|NSTE2VT9Mg Ml7ZZZR1\W63YYTld{B1cGVibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wIH;mJIhDTC1{IHnuJJJme3CxboPpeoUhfG9iRFG= MYKyOlIzOzJ3MR?=
MDA-MB-231 MYDGeY5kfGmxbjDBd5NigQ>? NFvTR2MzKM7:TR?= MlnENlQhcA>? MlSzcIV{e2WwZYOgR2NNOiCrbnT1Z5Rqd25iYomgWG5H|rF? M2HMXlI3OTByOES4
rBMSCs NXfBbHU5TnWwY4Tpc44hSXO|YYm= MoLCNVAh|ryP NF\pXZozNjViaB?= NV;obVBt\GWycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd25ib3[gSXJMKGGwZDDwN|g> M13yNVI3ODV|Mk[2
MG63 NYL5TWxzTnWwY4Tpc44hSXO|YYm= NHLoSngyOC9{MD:zNEDPxE1? M2nnTVI1KGh? MV\zbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgcIV3\Wxib3[gdIhwe3Cqb4L5cIF1\WRicEO4JIlv\HWlZXSgZpkhS2SFbEKgbY4h[SClb37j[Y51emG2aX;uJE1l\XCnbnTlcpQhdWGwbnXy MkjnNlU6QTh|MUK=
MG63 NIDhSXdCeG:ydH;zbZMhSXO|YYm= M3nEVFExNzJyL{OwJO69VQ>? M4jwR|I1KGh? M3LaWpNq\26rZnnjZY51dHliZHXjdoVie2WmIITo[UBieG:ydH;zbZMhemG2ZTDv[kBOTzZ|IHnu[JVk\WRiYomgR4REdDJ? MkDQNlU6QTh|MUK=
HTSMCs MoXuSpVv[3Srb36gRZN{[Xl? NUfIZWtmOC5zL{GvNVAh|ryP Ml[0NUBp NXnlPJZIcW6qaXLpeIVlKEORUl2tNk1qdmS3Y3XkJGhQNTFicILveIVqdiCuZY\lcJMh[W6mIH3SUmEh\XiycnXzd4lwdg>? MnjKNlU6OjF2NkS=
MIA PaCa-2 NE\kVXRHfW6ldHnvckBCe3OjeR?= MnLINlDDqM7:TR?= M17tN|I1KGh? MWLy[YR2[2WmIHzhZ5RifGViYXPjeY12dGG2aX;uJIlvKGOxbXLpcoF1cW:wIIfpeIgh[m:2aDCyMWRIKGGwZDDEMYFtdG:|ZdMg MormNlU5QDh2OEm=
MIA PaCa-2 M3TYVmZ2dmO2aX;uJGF{e2G7 M2eweFIxyqEQvF2= NYPZeYZHOjRiaB?= MVXy[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= NWnPWnNbOjV6OEi0PFk>
BxPC-3 NH;CbmJHfW6ldHnvckBCe3OjeR?= MX[yNOKh|ryP MmTTNlQhcA>? MUXy[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= NHLIVFgzPTh6OES4PS=>
AsPC-1 MlPnSpVv[3Srb36gRZN{[Xl? MVGyNOKh|ryP MlTMNlQhcA>? M2LLNpJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u MmXNNlU5QDh2OEm=
MIA PaCa-2 M3HJ[2Z2dmO2aX;uJGF{e2G7 MXOyNOKh|ryP Mki4NlQhcA>? NXv2NHBs\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEB4cGWwIHPvcYJqdmWmIIfpeIgh\2y3Y3;z[UBidmGub3fz NYjmUI9NOjV6OEi0PFk>
MIA PaCa-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYryW3VjOjEEoN88US=> M2r1cFIhcA>? NWrye5NJe2Wwc3n0bZpmeyClZXzsJIxqdmW|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On MnXCNlU5QDh2OEm=
BxPC-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLs[WFFOjEEoN88US=> M2nsZ|IhcA>? M3SwcJNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? MVSyOVg5QDR6OR?=
AsPC-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP5NlDDqM7:TR?= M331U|IhcA>? MULz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> NVfCOnZkOjV6OEi0PFk>
HEY M{C1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXeyNOKh|ryP M1e5VlIhcA>? M1fEb5NmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? MljBNlU5QDh2OEm=
OVCAR-3 MoGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHYW4wzOMLizszN M1nLOlIhcA>? NVTTc211e2Wwc3n0bZpmeyClZXzsJIxqdmW|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On NELj[4IzPTh6OES4PS=>
SK-OV-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:5TXM5OjEEoN88US=> Mn7FNkBp M{LLTpNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? NHPoSG4zPTh6OES4PS=>
MH7A  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPQNlQhcA>? M2THeJJmcW6ob4Lj[ZMhfGinIHnubIljcXSxcomg[YZn\WO2czDv[kBZSU5? NXPSfGh1OjV6NkK5OlY>
MH7A  NXL4U3B5SXCxcITvd4l{KEG|c3H5 MUeyOUDPxE1? MknZNlQhcA>? M1P5VJJmfmW{c3XzJINmdGxiY4njcIUh[XK{ZYP0JIlv\HWlZXSgZpkhYEGQIHHu[EBk[XW|ZXSgZZBweHSxc3nzJI9nKGOnbHzzJJZq[SCjY4TpeoF1cW:wIH;mJGpPUw>? Mn\oNlU5PjJ7Nk[=
SCC25 Mm\sSpVv[3Srb36gRZN{[Xl? Ml\mNlAh|ryP MYSyOEBp MUnpcoNz\WG|ZYOgZZV1d3CqYXf5JIxmfmWu NGrFNnczPTh|NESwNC=>
HaCaT  M1vOUGZ2dmO2aX;uJGF{e2G7 MnrTOUDDvU1? MX6yOEBp NUPF[pBzcW6qaXLpeJMhUU[QLd8zMYlv\HWlZXSgR2NNOjJicILv[JVkfGmxbjDs[ZZmdHN? NVrU[3BPOjV6M{SzOVM>
HaCaT  NFrMU2dHfW6ldHnvckBCe3OjeR?= MVy1JOK2VQ>? NUDadXpvOjRiaB?= MnPFbY5pcWKrdIOgTWZPNc7zLXnu[JVk\WRiQ1PMNlIheHKxZIXjeIlwdiCuZY\lcJM> NV[3b286OjV6M{SzOVM>
HPAEpiCs  MXzGeY5kfGmxbjDBd5NigQ>? M{X5U|EwOy9zMDFOwG0> MXmxJIg> MXvy[YR2[2W|IGOxVE1qdmS3Y3XkJGlESU1vMTDwdo91\WmwIHHu[EBuWk6DIHX4dJJme3Orb36gZY5lKHC{b33veIVzKGGldHn2bZR6 Ml3JNlU4OzR7MEC=
HPAEpiCs MVvGeY5kfGmxbjDBd5NigQ>? NIGzeFcyNzNxMUCg{txO M1\kcVEhcA>? NUHoe4kxcW6qaXLpeJMhWzGSLYP0bY12dGG2ZXSgRYt1KHCqb4PwbI9zgWyjdHnvckAhyqB? MXeyOVc{PDlyMB?=
HPAEpiCs M4fyZWZ2dmO2aX;uJGF{e2G7 NYG3W|F7OS9|L{GwJO69VQ>? NHixbGcyKGh? M33RUIlvcGmkaYTzJHMyWCC2aX3lMYRmeGWwZHXueIx6KHO2aX31cIF1\WRiYz3KeY4heGixc4Doc5J6dGG2aX;u MnnZNlU4OzR7MEC=
K562 NFTMSpFHfW6ldHnvckBCe3OjeR?= NXPnXIZ{OTEEoN88US=> Mn;uNeKhcA>? NVqwdnpQTE2VTx?= NETOWFVqdmirYnn0d{ByfWmwYXPybY5mNWmwZIXj[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u MonSNlU3QDRyNEO=
PANC-1 NXzteotFTnWwY4Tpc44hSXO|YYm= NYq4UJhWOTBizszN M3;oRVEhcA>? M{fDdoVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi NELIPZEzPTZ|MkKyNi=>
BxPC-3 NWq0V3J[TnWwY4Tpc44hSXO|YYm= MVuxNEDPxE1? Mlu3NUBp MXzlcohidmOnczD0bIUh[XW2b4DoZYdq[yCnZn\lZ5TDqA>? NEDlclYzPTZ|MkKyNi=>
K562  NHLGW4pHfW6ldHnvckBCe3OjeR?= NELQbIUxNjJ3LUGg{txO MXuyOEBp NVfqb5Fre3WycILld5NmeyC{ZYP2[ZJifHKxbD3pcoR2[2WmIFiyRXgheGixc4Doc5J6dGG2aX;u NImyVnkzPTZzOUO5Ni=>
THP-1 MVrGeY5kfGmxbjDBd5NigQ>? NYrnNnFJPSEEtV2= Ml\4NkBp M1G3WpNq\26rZnnjZY51dHliYYT0[Y52[XSnczDz[YNz\XSrb36gc4YhUUxvMd8xJIlv\HWlZXSgZpkhOjeRSFPoc4wheGy3czDGV2wuOcLi NUXq[2MyOjV3OUi2OlE>
WB NGLiVoZHfW6ldHnvckBCe3OjeR?= M2jXZVIx6oDLzszNxsA> M3y3fFMx6oDLbXnu NHLxWnNl\WO{ZXHz[ZMhfGinIFzQV{0hd3JiTGTBMYlv\HWlZXSgTWwuPiCjbnSgWG5HNc7zwrDwdo9lfWO2aX;u M1zrR|I2PTNyNkiy
RAW 264.7 NUDt[lQ{TnWwY4Tpc44hSXO|YYm= NYP6PXNMOTEEoN88US=> NHLxWXM{OOLCiX3pci=> NUP0dINucW6mdXPld{BkcGG{YXP0[ZJqe3SrYzD2ZYN2d2yjdHnvckBw\iCRQ4RCpC=> NFLjeG0zPTR4MUO5PS=>
RAW 264.7 NU\3fVNVTnWwY4Tpc44hSXO|YYm= MmfXNVDDqM7:TR?= M1LZZVMx6oDLbXnu MU\heJRmdnWjdHXzJJRp\SCnZn\lZ5R{KG:oIF;QS{BwdiCxc4Tlc4Nt[XO2IILleJJi[3Srb36= MXqyOVQ3OTN7OR?=
HaCaT  NVPNWo1ZTnWwY4Tpc44hSXO|YYm= MUm0NOKh|ryP MXyzMVI1KGh? NViwcYJ2TE2VTx?= MXvy[YR2[2W|IITo[UBi[2O3bYXsZZRqd25ib3[gXm8uOQ>? NHHrbJYzPTR|NUS4OS=>
H9c2 NFvoVZRHfW6ldHnvckBCe3OjeR?= MmO5OVDDqM7:TdMg M{K3RlEzKGh? MWLy[YR2[2W|IFzETEBz\WynYYPlJIFv\CCPTWCgcI9{ew>? NXH2S5dGOjV{NEW4NVg>
HSCs NUDVSmQ2SXCxcITvd4l{KEG|c3H5 M2PV[|I2KM7:TR?= M3\nZVI1yqCq NGq3e5l{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgWGcucW6mdXPl[EBi[3SrdnH0[YQhUFOFczDhdI9xfG:|aYO= MlnoNlQ6PjF7NUC=
THP-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[4cJk4OiCq NVG5VJFRTE2VTx?= MYLJR|UxRTRwN988US=> NWDmTVk{OjR6MUWwPFc>
MDDCs MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjDRW9vPzJiaB?= MWrEUXNQ MmS2TWM2ODJwN988US=> NUft[HRuOjR6MUWwPFc>
MDDCs MmHPSpVv[3Srb36gRZN{[Xl? MnvTNE0yPSEQvF2= M2T1e|Q5KGh? NHPqcJhFVVOR MXLzeZBxemW|c3XzJGlHVi4QsTDhcoQhUVBvMUCgdJJw\HWldHnvcuKh NWjQdmZvOjR6MUWwPFc>
MDDCs NGfTRXhHfW6ldHnvckBCe3OjeR?= MljsNE0yPSEQvF2= MVG0PEBp NXPH[mpwTE2VTx?= NH63VINqdmirYnn0d{BOUVBvMXGsJG1KWC1zYjDhcoQhWkGQVFXTJJBzd2S3Y4Tpc44> M3;abVI1QDF3MEi3
MDDCs NWjkZmJqTnWwY4Tpc44hSXO|YYm= MmTsNVAh|ryP NFnNbVg{NjViaB?= MYjEUXNQ M4PB[oJtd2OtczDFRm9XKEeSLDDieZQhdm:2IG\TWkBIKG2nZHnheIVlKGWwdIL5JIlvfG9iaIXtZY4hVUSGQ4O= MWGyOFgyPTB6Nx?=
macrophages MlTxSpVv[3Srb36gRZN{[Xl? MVix5qCK|ryP NXjjSXhZPC534pEJbC=> NX;DVGdj[2:vcHzleIVtgSCrbnjpZol1eyCPVD3JTWkucW6mdXPl[EBi[3SrdnH0bY9vKG:oIF7GMe67Sg>? NYPndJJGOjR6MEi2N|M>
PDL  MXXGeY5kfGmxbjDBd5NigQ>? NIjKW5YzOMLizszNxsA> M1XSbFMxKG2rbh?= MmHTSG1UVw>? MnzYd4lodmmoaXPhcpRtgSCrbnjpZol1eyC2aHWgeIVve2muZTDmc5Jk\S2vZXTpZZRm\CCETWCtNkBmgHC{ZYPzbY9v NYDGTXJKOjR3NkGwPFE>
AGS MXvGeY5kfGmxbjDBd5NigQ>? NI\KV2Y2KM7:TR?= NGLOZmQ{OCCvaX6= M3nRfJN2eHC{ZYPz[ZPDqDFvaX7keYNm\CClYYPwZZNmNThiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v MVGyOFU1Pzh5OB?=
H520 MVTGeY5kfGmxbjDBd5NigQ>? M{TkVFExyqEEtV2= M2XENVEhcA>? NXvWWppUTE2VTx?= NWXHUWl5\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=> NWno[pprOjR3M{C0O|U>
H1703 MUXGeY5kfGmxbjDBd5NigQ>? NWjHUpZnOTEEoNM1US=> MkDrNUBp NVzDUI5GTE2VTx?= NFHj[oVl\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz NYfiPIsyOjR3M{C0O|U>
H520 M1vvemZ2dmO2aX;uJGF{e2G7 M1jGSVExyqEEtV2= MUixNkBp NYXEW2lXTE2VTx?= NGXxVodqdmirYnn0d{Bx\W2ndILlfIVlNWWuaXPpeIVlKE2VSEKgdJJwfGWrbjDzeIFjcWyrdIm= MnnNNlQ2OzB2N{W=
H1703 NHTQPGNHfW6ldHnvckBCe3OjeR?= Mkm2NVDDqML3TR?= NV7XOIl7OTJiaB?= NYDnXnFZTE2VTx?= MnLPbY5pcWKrdIOgdIVu\XS{ZYjl[E1mdGmlaYTl[EBOW0h{IIDyc5RmcW5ic4ThZoltcXS7 M3zIb|I1PTNyNEe1
H520 M3nZOWZ2dmO2aX;uJGF{e2G7 NUHkWIVPOTEEoNM1US=> NHz3UIY3KGh? M176XWROW09? Mmjvd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n NEDtOWMzPDV|MES3OS=>
H1703 NYW3TJFrTnWwY4Tpc44hSXO|YYm= MnT6NVDDqML3TR?= NIHCcYw3KGh? NXn2WYZyTE2VTx?= MnLBd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNidHjlJIxmfmWuczDv[kB2[mmzdXn0bY4u[2:waoXnZZRm\CCPU1iyJIlvKHCnbXX0doV5\WRvdILlZZRm\MLiY3XscEBtcW6n MUSyOFU{ODR5NR?=
MC3T3-E1 M1vibmZ2dmO2aX;uJGF{e2G7 MVywMlMwOy9|MDFOwG0> NE\LbGYyKGh? M2mydoF1fGWwdXH0[ZMhXE6ILd8xMYlv\HWlZXSgUW1RNTliZYjwdoV{e2mxbjDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nctMg NWfIU4ZVOjR3MEK2PVY>
MC3T3-E1 M{TLN2Z2dmO2aX;uJGF{e2G7 MnvkN|Ah|ryP MWSxJIg> M4T0cIF1fGWwdXH0[ZMhXE6ILd8xMZN1cW23bHH0[YQheDN6IF3BVGsheGixc4Doc5J6dGG2aX;u MlnkNlQ2ODJ4OU[=
HUVECs  MnzoSpVv[3Srb36gRZN{[Xl? NUnIdWtvOTEEoNM1US=> M{G2dlEhcA>? MXzpcohq[mm2czDUUmYu|rFvaX7keYNm\CCFWFPMNUBxem:mdXP0bY9v M4fObFI1PDh5OU[0
AGS  NF\BSmZHfW6ldHnvckBCe3OjeR?= M{f1TlExyqEEtV2= MlvsN|DDqG2rbh?= NVv4NnhPcW6qaXLpeJMhUUxvMd8yMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{i= M371UVI1PDd7Nkix
MKN-45 M3;T[mZ2dmO2aX;uJGF{e2G7 MXWxNOKhyrWP Mlf3N|DDqG2rbh?= NHnNWWtqdmirYnn0d{BKVC1zzsKtbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB|OB?= MV2yOFQ4QTZ6MR?=
AGS  M4PwOGZ2dmO2aX;uJGF{e2G7 Mn6wNVDDqML3TR?= NUHpUHNNOzEEoH3pci=> NUHTOpFr[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25? MXuyOFQ4QTZ6MR?=
MKN-45 NV;xV5VKTnWwY4Tpc44hSXO|YYm= NEDQb3kyOMLiwsXN MnXvN|DDqG2rbh?= NVnw[ppv[XS2ZX71ZZRmeyCLTD2x{tIucW6mdXPl[EBISSClZXzsJI1q\3KjdHnvckBidmRiaX72ZZNqd25? NUDY[2tbOjR2N{m2PFE>
AGS  NEfxPWZHfW6ldHnvckBCe3OjeR?= MUmxNOKhyrWP NGPtV3Y{OMLibXnu M3jwdpNq\26rZnnjZY51dHliZHXjdoVie2W|IFnsMVHPui2rbnT1Z4VlKE2PUEKgZY5lKE2PUEmgcXJPSSCneIDy[ZN{cW:w NIPXfmYzPDR5OU[4NS=>
MKN-45 M{fPZ2Z2dmO2aX;uJGF{e2G7 MlqxNVDDqML3TR?= NEno[2o{OMLibXnu MmHKd4lodmmoaXPhcpRtgSCmZXPy[YF{\XNiSXytNe6zNWmwZIXj[YQhVU2SMjDhcoQhVU2SOTDtVm5CKGW6cILld5Nqd25? NYLjTGZVOjR2N{m2PFE>
DCs NWTrWI86TnWwY4Tpc44hSXO|YYm= NETQXWYzOMLizszN MmLHNeKhcA>? M1;LbIRm[3KnYYPld{BKVC1zMjDwdo9lfWO2aX;u MnzTNlQ1OzR4M{[=
HUVEC  NGS3dppHfW6ldHnvckBCe3OjeR?= MUmyNEDPxG4EoB?= NY\2TVFMPSCq NYrMZo1XTE2VTx?= NWDjRm5PemWmdXPld{BkgXSxa3nu[UBmgHC{ZYPzbY9vKGyndnXsd{BqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M3zEdVI1OTh7ME[y
A 549 NGrIXXlHfW6ldHnvckBCe3OjeR?= M2\J[VUxKM7:TR?= NYH2cWFwOSCq MXHk[YNz\WG|ZYOgeIhmKGyndnXsJI9nKEmOLUlCpC=> NIjzZW8zPDF5OU[4PC=>
H520  NX:1elVETnWwY4Tpc44hSXO|YYm= M33seFUwOTBizszN NUewfnVtOSCq M2O2fWROW09? NVi5PIV7\GWlcnXhd4V{KE2VSEKgdJJwfGWrbjDhd{B4\WyuIHHzJI1TVkFibHX2[Yx{KGmwIHfl[ol1cW6rYj3lfJBwe2WmIHPlcIw> NFfOW2QzPDF|OEmwNy=>
H1703  NVnST4tETnWwY4Tpc44hSXO|YYm= MUm1M|ExKM7:TR?= M3jvNFEhcA>? MoPwSG1UVw>? M1PDSYRm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs Mon3NlQyOzh7MEO=
H520  MkTQSpVv[3Srb36gRZN{[Xl? NWHr[pBoOTEEoNM1US=> MVmxNkBp MljtSG1UVw>? NFjtXIdl\WO{ZXHz[ZMhVVOKMjDtVm5CKGGwZDDwdo91\WmwIIP0ZYJqdGm2eTDpckBo\W[rdHnubYIufHKnYYTl[EBPW0OOQzDj[Yxtew>? NGnWRWYzPDF|OEmwNy=>
H1703  MmfsSpVv[3Srb36gRZN{[Xl? NFHZSWYyOMLiwsXN NFPFWmgyOiCq NILqU|RFVVOR M4\aZoRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{ NXPWdFZqOjRzM{i5NFM>
MCF-7  M{DHeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vme|ExyqEQvF2= MUKyOOKhcA>? M2myXYlvcGmkaYTzJJRp\SCFUkGwPE1qdmS3Y3XkJINmdGxiZHXheIg> Mmf4NlQyOjh6NUO=
HPAEpiCs MnX1SpVv[3Srb36gRZN{[Xl? NXi4WoNXOC5zL{GvNVAh|ryP NG\FZpQyKGh? Ml3SbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiY2DMRVLDqHC{b4TlbY4h[W6mIH3SUmEh\XiycnXzd4lwdg>? M4HLZlI1ODZ7MUW4
podocytes MoniSpVv[3Srb36gRZN{[Xl? NEnwW3UyOMLizszN MVmxJIg> NVrhbm85cW6qaXLpeJMhXEeIzsKxMYlv\HWlZXSgZYN1cX[jdHnvckBw\iCyM{jNRXBMKGGwZDDFdosyNzMEoB?= NWXZNWhUOjRyM{[yNVI>
MCF-7 NUPsXG03TnWwY4Tpc44hSXO|YYm= NUXhSohwOTEEoN88US=> M{jIPVEhcA>? M1zHZ2ROW09? NFK2dolz\WS3Y3XzJJRp\SCZQT3pcoR2[2WmIIDoc5NxcG:{eXzheIVlKHB|ODDNRXBM NUT4cYpFOjRyMUmwPVA>
MCF-7 NGnNWldHfW6ldHnvckBCe3OjeR?= M2Lte|ExyqEQvF2= NHTyPYozPCCq M2nyRWROW09? NWnw[nM6cW6lcnXhd4V{KHSqZTDXRU1qdmS3Y3XkJIFxd3C2b4Ppdy=> MnjFNlQxOTlyOUC=
HAPI NH\OUohHfW6ldHnvckBCe3OjeR?= NXHtfIhPOTBxMkCvOFDDqM7:TR?= M37MZ|EhcA>? MVPpcohq[mm2czDUR2RFNWmwZIXj[YQheDN6L1rOT{BOSVCNIIDoc5NxcG:{eXzheIlwdg>? NF\tXZEzOzl4OUGyNC=>
HAPI MV7GeY5kfGmxbjDBd5NigQ>? NF;5Z3kzOMLizszNxsA> MlPvNUBp M{XQTWROW09? MXnheJRmdnWjdHXzJHRETERvaX7keYNm\CCjY4TpeoF1cW:wIH;mJIlPV1NiYX7kJJBzd2S3Y4Tpc44> M3HoV|I{QTZ7MUKw
HepG2 Mn\HSpVv[3Srb36gRZN{[Xl? NIK0[lg{PTBibl2= M4G4bFI1KGh? M4PKb4lvcGmkaYTzJJRp\SCmZXf1[Yxqdi2rbnT1Z4VlKGGldHn2ZZRqd25ib3[gdFM5VUGSSx?= NEPIXWYzOzl|M{G5PC=>
AGS  M4L0U2Z2dmO2aX;uJGF{e2G7 NG\5WlkyOMLizszN Mnn1N|AhdWmw MoPVbY5pcWKrdIOgZ4F{eGG|ZT2zJIFkfGm4YYTpc44h[W6mIHnubIljcXSrb36gc4YhTVKN NUPBbVhbOjN6NUC5PVQ>
HepG2 NX;JVHR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCwMVUxKM7:TR?= MmP0OFghcA>? MlThbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NVXBS4IxOjN6MEe1NFg>
BEL7404 M{S1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOwMVUxKM7:TR?= NULzOlNrPDhiaB?= MUfpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NX3ldJRYOjN6MEe1NFg>
HL7702 NHHJXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnUNE02OCEQvF2= MUC0PEBp NUTTZYdicW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M1PFXFI{QDB5NUC4
HepG2 MYDGeY5kfGmxbjDBd5NigQ>? NF;tR|MxNTVyIN88US=> MkLTNlQhcA>? MoHXbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCyM{ig[I94dnO2cnXhcUBxem:2ZXnud{BOSVCNQWDLNkwhSVSIMjygUXNMOSCjbnSgTHNROjdiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUfJOmNNOjN6MEe1NFg>
BEAS-2B MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIq4TncyOCEQvF2= NHfUb3I{OCCvaX6= NImwcGhz\X[ncoPld{B1cGViZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHliaX7keYNm\CCkeTDIR2k> NV\FToNROjN5OESwN|Q>
BEAS-2B Mn3IR5l1d3SxeHn0fUBCe3OjeR?= MUKxNEDPxE1? MlXDN|AhdWmw MoTrbY5pcWKrdHXkJJRp\SCrbnPy[YF{\SCrbjDMSGgh[W6mIFnMMVgh\XiycnXzd4lwdg>? M37lUlI{Pzh2MEO0
BEAS-2B NHvQ[oJHfW6ldHnvckBCe3OjeR?= NEK3V20yOCEQvF2= M3zyUFMxKG2rbh?= NHHTcVFl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjZZNx[XOnLUOsJGJi\CCjbnSg[oF{ MoG3NlM4QDRyM{S=
H9c2  NX:xZoViTnWwY4Tpc44hSXO|YYm= NYi5RXZjOC5yMT:wMlEwOSEQvF2= MWGxJIg> NGrLR3RifHSnboXheIV{KFSQRj5OtU1qdmS3Y3XkJG1OWC17IHX4dJJme3Orb36sJI1TVkFibHX2[Yx{NCCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm= M{Cxb|I{Pzd2MkWy
H9c2  MXrGeY5kfGmxbjDBd5NigQ>? Mm\XNUDPxE1? MoT5NUBp MWny[YR2[2W|IGTOSk3PuSCmaYLlZ5RtgSC|dHnteYxifGWmIICzPEBOSVCNIIDoc5NxcG:{eXzheIlwdg>? NG\ocZEzOzd5NEK1Ni=>
U937 NYnVVGhUTnWwY4Tpc44hSXO|YYm= MWexNOKh|ryPwrC= NHPzUIsyKGh? MXnhZpJw\2G2ZYOgeIhmKGOjZn\lbY5mKGWoZnXjeEBwdiCPS2CtNUBidmRiUGCyRYPPuSCvUl7BJJRz[W6|Y4LpdJRqd26jbDDs[ZZmdHN? NFvh[VUzOzdyN{O4Oy=>
U937 MlfnSpVv[3Srb36gRZN{[Xl? MojTNVDDqM7:TdMg M3nYbFEhcA>? M{L5SoFjem:pYYTld{Bk[W[oZXnu[U1qdmS3Y3XkJG1MWC1zIHTve44uemWpdXzheIlwdiCjbnSgVHAzSWQQsTD1dE1z\We3bHH0bY9v MViyN|cxPzN6Nx?=
U937 NF;4WWlHfW6ldHnvckBCe3OjeR?= MoTNNVDDqM7:TdMg NVPtPWVwOSCq NH;RUGV{fXCycnXzd4V{KGNvSoXuJIFv\CCFUlXCJJBpd3OyaH;yfYxifGmxbjDpckBk[W[oZXnu[U11emWjdHXkJINmdGy|wrC= MWKyN|cxPzN6Nx?=
A549 NXHHOll[TnWwY4Tpc44hSXO|YYm= Ml\ENE4{NzNxM{Cg{txO MnHaNUBp MX7zbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiQWTQ{tNUNW2nZHnheIVlKEORWD2yJJBzd3SnaX6gZY5lKG2UTlGg[ZhxemW|c3nvckBidmRicILvcY91\XJiYXP0bZZqfHoEoB?= MmX6NlM3QDB4N{S=
A549 M4TSSWZ2dmO2aX;uJGF{e2G7 NXz5NHBLOTEEoN88UeKh MVuwMVMxKG2rbh?= NWHid29VcW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgdFQzN3B2NDDNRXBMKGGwZDDwN|ghVUGSSzDwbI9{eGixconsZZRqd25? M3X5NFI{PjhyNke0
A549 NHf4eFJHfW6ldHnvckBCe3OjeR?= M2nFflExyqEQvF5CpC=> NUXiT5l5OSCq M2nsS4lvcGmkaYTzJGFVWM7|UzDpcoR2[2WmIF7GMe67SiCyNkWgd5VjfW6rdDDwbI9{eGixconsZZRqd25iYX7kJG5HNc78QjDwdo9ud3SncjDhZ5Rqfmm2eR?= MmH0NlM3QDB4N{S=
A549 NYKyPJA3TnWwY4Tpc44hSXO|YYm= M2rlTlExyqEQvF5CpC=> M3TrN|EhcA>? NGX5WGNz\WS3Y3XzJGFVWM7|Uz3zeIlufWyjdHXkJINRVEF{IIDoc5NxcG:{eXzheIlwdsLi NED2cXAzOzZ6ME[3OC=>
A549 NXfjSXJOTnWwY4Tpc44hSXO|YYm= M13PNFExyqEQvF5CpC=> NGr6PZkyKGh? MmTodoVlfWOnczDBWHDPu1NvZX7oZY5k\WRiZX76fY1ifGmlIHHjeIl3cXS7IH;mJINRVEF{wrC= MmHhNlM3QDB4N{S=
PC12 MkTTSpVv[3Srb36gRZN{[Xl? NWf4NY5bOTBxMkCvOFAh|ryP NVHwOpk6OcLiaB?= Ml7kbY5pcWKrdIOgTm5MKGGwZDDwN|g> NEnmWokzOzV6NEO1Oy=>
HK-2 MkDURZBweHSxc3nzJGF{e2G7 MYiyNOKh|ryP MmTiNlQhcA>? NIC4bJdqdmirYnn0d{BGWktiYX7kJJA{QE2DUFu= Mn3XNlM2PDNzNUG=
H9c2 NELNOmlHfW6ldHnvckBCe3OjeR?= NGfOS|IyyqEQvF2= NV7xXJVbOSCq MVHy[YR2[2W|IGTOSk3PuS2rbnT1Z4VlKE2PUD25JI1TVkFibHX2[Yx{KGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?= MUSyN|M2OzZ7OR?=
H9c2 M1v1UmZ2dmO2aX;uJGF{e2G7 M3LEcVHDqM7:TR?= NV\o[Xp6OSCq M3WyOJJm\HWlZYOgWG5HNc7zLXXubIFv[2WmIFHQMVEheHKxbX;0[ZIh[WO2aY\peJk> NHH0Z24zOzN3M{[5PS=>
H1650  MUXGeY5kfGmxbjDBd5NigQ>? NH7uT2QyOMLizszNxsA> NFTPPIEyKGh? NETQe3VFVVOR NV64S3A2\GWlcnXhd4V{KGKxdHigdJJwfGWrbjDhcoQhdVKQQTDs[ZZmdHNib3[gSXJESzFiaX6gdIFkdGm2YYjlcE1mgHCxc3XkxsBk\Wyucx?= MXGyN|IzQDZ7Nh?=
H1703 M4XPVWZ2dmO2aX;uJGF{e2G7 MmTwNVDDqM7:TdMg M2XlN|EhcA>? MmnlSG1UVw>? MlzG[IVkemWjc3XzJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcJMhd2ZiRWLDR|EhcW5icHHjcIl1[XinbD3lfJBwe2WmwrDj[Yxtew>? NELCSm0zOzJ{OE[5Oi=>
H1650  MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX3NVDDqM7:TdMg NIDvNHMyKGh? NVT2OXVKTE2VTx?= MYflcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NWTkbId{OjN{Mki2PVY>
H1703 NUnkNVdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXpbopwOTEEoN88UeKh NV3aemI1OSCq M4TWdmROW09? M3rSOIVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBkgXSxdH;4bYNqfHl? MlnhNlMzOjh4OU[=

... Click to View More Cell Line Experimental Data

In vivo Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

+ Expand
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 12 mg/mL (36.21 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products4

Tags: buy SB202190 (FHPI) | SB202190 (FHPI) supplier | purchase SB202190 (FHPI) | SB202190 (FHPI) cost | SB202190 (FHPI) manufacturer | order SB202190 (FHPI) | SB202190 (FHPI) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID